Myopia Management: Why Slowing Progression Matters More Than the Prescription

Myopia — commonly called nearsightedness — is one of the fastest-growing ocular health concerns worldwide. It is no longer simply a refractive inconvenience corrected by glasses or contacts. When left unmanaged, progressive myopia significantly increases the lifetime risk of serious, sight-threatening conditions including retinal detachment, myopic maculopathy, glaucoma, and early-onset cataracts.¹ The higher the final prescription, the greater that risk becomes — which is precisely why intervening early, rather than simply updating prescriptions year after year, changes the long-term trajectory for your child.

Your Annual Exam Is About More Than Your Prescription

Glasses and contacts are important — but they are only part of what we do at your child's annual wellness exam. Correcting their vision so they can see the board at school is the immediate goal. Monitoring whether their myopia is progressing — and at what rate — is the longer-term one that protects their eye health for decades to come.

Our primary goals during every wellness exam are to determine the most accurate prescription and to screen for early signs of progressive myopia. If the findings warrant a more structured management approach, we schedule a dedicated follow-up visit to discuss treatment options, set a baseline, and build a monitoring plan tailored to your child specifically.

When Do We Start the Conversation?

Myopia management is not reserved for teenagers with strong prescriptions. We begin evaluating risk as early as kindergarten — ages four to five — because the earlier progression is identified and addressed, the more intervention can accomplish.

The decision to initiate treatment is based on a combination of factors rather than prescription alone. A child with two myopic parents carries a substantially elevated genetic risk.² A prescription that is high relative to a child's age, or one that has changed significantly within a single year, signals a pattern worth addressing proactively. We also perform a cycloplegic — or "wet" — refraction, which temporarily relaxes the focusing muscles of the eye to reveal the true underlying prescription without the influence of accommodative effort. This gives us a more accurate and reliable baseline than a standard refraction alone.

What Myopia Management Actually Does

It is important to set realistic expectations upfront: myopia management does not reverse a prescription or cure nearsightedness. The goal is to slow the rate of progression — to reduce how much the prescription changes over time, and in doing so, reduce the final endpoint prescription your child reaches in adulthood. Even modest reductions in final axial elongation carry meaningful reductions in long-term disease risk.³

Time spent outdoors has also been shown to have a protective effect against myopia onset and progression, with studies suggesting approximately 90 minutes of outdoor exposure per day is beneficial.⁴ This is one of the simplest, most accessible recommendations we make to families alongside any clinical treatment.

Treatment Options We Offer

Essilor Stellest Lenses are our preferred first-line recommendation for most patients. These are spectacle lenses — ordinary glasses — engineered with H.A.L.T. (Highly Aspherical Lenslet Target) technology that creates a volume of signal in front of the peripheral retina to slow eye elongation. Clinical data shows a 67% reduction in myopia progression on average compared to standard single-vision lenses.⁵ Because they function as everyday glasses, they require no insertion, no overnight wear, and no compliance burden beyond simply wearing the prescription the child already needs. This makes them accessible for virtually all school-age patients regardless of age or lifestyle.

Soft Multifocal Contact Lenses are an option for appropriate candidates who are contact lens-ready. These lenses use a dual-focus or extended depth-of-focus design to reduce the peripheral hyperopic defocus signal thought to drive axial elongation. They require a higher level of patient compliance and maturity than spectacle-based treatment.

Low-Dose Atropine is a topical eye drop therapy used to pharmacologically slow myopia progression. It is typically considered when other methods are insufficient or as a complementary approach, and is dosed at low concentrations to minimize side effects. This is discussed on an individualized basis during the medical visit.

Addressing the Cost Conversation Honestly

Myopia management is an out-of-pocket investment for most families, and we understand that is a real consideration. Our approach is to be transparent: these treatments require a financial commitment, and we will never minimize that. What we ask parents to weigh against that cost is the alternative — an unchecked prescription that climbs through childhood and adolescence, compounding lifetime risk for conditions that are far more expensive, far more difficult to manage, and far less reversible than myopia itself. We are happy to walk through the options and find an approach that is clinically appropriate and workable for your family.

The Bottom Line

Myopia is not simply a vision problem — it is a public health concern with real long-term consequences when ignored. If your child is myopic, has myopic parents, or has shown meaningful prescription changes at a young age, the time to have this conversation is now. Contact us to schedule an evaluation and we will give you a clear picture of where things stand and what the options are.

For educational purposes only. Not a substitute for individualized medical care.

Myopia Management

1. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622–660.

https://doi.org/10.1016/j.preteyeres.2012.06.004

2. Mutti DO, et al. Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci.

2002;43(12):3633–3640. https://iovs.arvojournals.org/article.aspx?articleid=2123938

3. Tideman JWL, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol.

2016;134(12):1355–1363. https://doi.org/10.1001/jamaophthalmol.2016.4009

4. He MG, et al. Effect of time spent outdoors at school on the development of myopia among children. JAMA. 2015;314(11):1142–1148.

https://doi.org/10.1001/jama.2015.10803

5. Bao J, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022;106(8):1171–1176. https://doi.org/10.1136/bjophthalmol-2020-318367